Oramed Pharmaceuticals (ORMP) Other Non-Current Assets (2012 - 2026)

Oramed Pharmaceuticals has reported Other Non-Current Assets for 13 years, with the latest figure at $2000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets fell 93.75% year-over-year to $2000.0; the trailing twelve-month figure through Mar 2026 stood at $2000.0 (down 93.75% YoY), and the FY2025 full-year result was $2000.0, changed 0.0% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $2000.0, roughly flat from $2000.0 in the prior quarter.
• The five-year high for Other Non-Current Assets was $111.5 million in Q4 2022, with the low at $2000.0 in Q2 2024.
• Historically, Other Non-Current Assets has averaged $8.6 million across 5 years, with a median of $6000.0 in 2023.
• Annual changes were most pronounced in 2023 — Other Non-Current Assets sank 99.99% — and 2025, when it surged 1800.0%.
• Oramed Pharmaceuticals' Other Non-Current Assets stood at $111.5 million in 2022, then slumped by 99.99% to $7000.0 in 2023, then sank by 71.43% to $2000.0 in 2024, then changed by 0.0% to $2000.0 in 2025, then changed by 0.0% to $2000.0 in 2026.
• The last three Other Non-Current Assets figures came in at $2000.0 (Q1 2026), $2000.0 (Q4 2025), and $2000.0 (Q3 2025), per Business Quant data.